Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE)

• Status: Completed
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy and safety of the fix-dose combination therapy with Gemigliptin 50mg and Rosuvastatin 20mg with type 2 diabetes and dyslipidemia

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: LG Life Sciences
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Type 2 Diabetes Mellitus with Dyslipidemia

• Adults who are at least 19 years old

Exclusion Criteria:

• Patients with type 1 diabetes, diabetic ketoacidosis, diabetic coma and pre-coma

• Patients with gestational diabetes or secondary diabetes

• Patients with NYHA Class III, IV congestive heart failure or arrhythmias requiring treatment

• Patients with thyroid gland dysfunction deviating from the normal TSH range

• Patients with pituitary insufficiency or adrenal insufficiency